Skip to main content
Toggle navigation
Search
Home
Icon Legend
Food/Drinks Available
CE's Available
Reception
Pre-registration Required
Livestreaming
Recorded Session
Home
Browse by Presenter
Browse by Presenter
Browse by Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Akmal, Sabah
UCLA Medical Center
PCM - Pediatrics to Geriatrics: Our Delicate Dance in CF
Location:103 AB
Sabah Akmal
Akong, Kathryn
University of California, San Diego and Rady Children's Hospital, San Diego
PGR1 - Severe Psychiatric Complications Related to CFTR modulator Use in a Teenager with Cystic Fibrosis
Location:118 ABC
Kathryn Akong
Alam, Faiyza
University of Toronto
TPS03.9- Elexacaftor/tezacaftor/ivacaftor treatment in pediatric cystic fibrosis lung disease reduces ventilation heterogeneity measured with hyperpolarized
129
Xe multiple-breath washout MRI.
Location:Hall B- TPS Theater
Faiyza Alam
Alao, Melissa
Boston Children's Hospital
JICR - Junior Investigators Best Abstract in Clinical Research
Location:103 C
Melissa Alao
PCM - Pediatrics to Geriatrics: Our Delicate Dance in CF
Location:103 AB
Melissa Alao
W17.4-
Implementing a Social Determinants of Health (SDoH) screener in a large pediatric Cystic Fibrosis Center
Location:203 B
Melissa Alao
Alba-Suarez, Juliana
Children's Health Dallas
CC02.2 - Blurred Lines: When Homelessness and Adherence Collide
Location:119 B
Juliana Alba-Suarez
Albon, Dana
UVA Health System
S12--The Future of CF Care: Managing Complexity, Cost, & Equity*
Location:118 ABC
Dana Albon
Alicandro, Gianfranco
Università degli Studi di MilanoFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
TPS02.3-
Covid-19 in cystic fibrosis patients compared to the general population: severity and virus-host cell interactions
.
Location:Hall B- TPS Theater
Gianfranco Alicandro
Allaire, Normand
Cystic Fibrosis Foundation
W36.1-
Modulation of
CFTR
intron 22 alternative polyadenylation (ApA) usage may have therapeutic potential for the treatment of certain 3’
CFTR
PTC variants.
Location:118 ABC
Normand Allaire
Altman, Kimberly
New York Presbyterian/Columbia University Irving Medical Center
L&L03 - GI Complications
Location:204 C
Kimberly Altman
Alton, Eric
National Heart and Lung Institute, Imperial College London
S01.4 -Pseudotyped lentivirus- mediated CFTR delivery
Location:108 AB
Eric Alton
Amaral, Margarida
Univ. de Lisboa, Faculty of Sciences
S24--Role of CFTR During Epithelial Development, Differentiation, & Regeneration
Location:119 A
Margarida Amaral
Anderson, Melanie
Cincinnati Children's Hospital Medical Center
PF.5 - Use of emerging treatment strategies for
mycobacterium abscessus
infection in an adolescent with advanced cystic fibrosis to optimize candidacy for lung transplantation
Location:118 ABC
Melanie Anderson
Anderson, Virginia
Children's of Alabama
DG05 - Advancing the Role of the RD: Beyond BMI
Location:105 AB
Virginia Anderson
Antell, Martine
University of Vermont Medical Center
R49 - 'The Dark Side of HEMT' - Trikafta Adverse Effects Beyond the Package Insert
Location:Ballroom B
Martine Antell
Antos, Nicholas
Children's Wisconsin and the Medical College of Wisconsin
RFPT07 - Rapid Fire Poster Talk 7: Clinical- Quality Improvement
Location:Exhibit Hall- RFPT A
Nicholas Antos
Argel, Natalia
Phoenix Childrens
DG12 - Hot Topics in CF Care for Nurses
Location:105 AB
Natalia Argel
Armbruster, Catherine
University of Pittsburgh
RFPT12 - Rapid Fire Poster Talk 12: Infection, Microbiology, & Immunity
Location:Exhibit Hall- RFPT B
Catherine Armbruster
Arora, Kavisha
Cedars Sinai Medical Center
W04--Emerging Topics in CFTR Cellular Biology
Location:Ballroom A
Kavisha Arora
Arrow, Alexander
Good Shepherd Penn Partners
DG15 - Treatment for all: Unique Situations in PT Care
Location:204 AB
Alexander Arrow
Ashare, Alix
Dartmouth-Hitchcock Medical Center
S16--Contribution of CFTR to Innate Airway Defense
Location:115 C
Alix Ashare
Ashkenazi, Moshe
Edmond and Lily Safra Children's Hospital, Sheba Medical Center
CC03.4 - A novel Airway Clearance device in bridge to Double Organ Transplantation
Location:204 C
Moshe Ashkenazi
Assis, David
Yale School of Medicine
W09.2- New CF Liver Disease Guidelines: Recommendations for Screening
Location:121 C
David Assis
Avizur Barchad, Ofra
Splisense Ltd. Jerusalem, Israel
RFPT02.2 - Antisense Oligonucleotide-Based Drug Development for Cystic Fibrosis Patients Carrying the 2789+5 G-to-A Splicing Mutation
Location:Exhibit Hall- RFPT B
Ofra Avizur Barchad
TPS04.7 - Antisense Oligonucleotide Splicing Modulation as a Novel Cystic Fibrosis Therapeutic Approach for the W1282X Nonsense Mutation
Location:Hall B- TPS Theater
Ofra Avizur Barchad
Back to Top
